Investing

Precision Medicine: The next trend in healthcare innovation

Current trends in healthcare technology will deliver future innovations to personalize healthcare. Identifying the right trends can benefit your investments.


The world anxiously awaits a vaccine for COVID-19—a one-size-fits-all solution to stop the pandemic now sweeping the globe. But also on the horizon is a supremely customized approach to healthcare that promises to transform how we diagnose and treat disease: precision medicine.

Many think this is the future of healthcare and that it is fast approaching. Precision medicine aims to deliver the most effective treatment tailored to a specific patient at the most opportune time to achieve the best possible result. This medical model depends on marrying a deep understanding of each person with comprehensive knowledge of all treatment options that might work for that individual, including at the genetic, molecular or cellular level.  

It’s thought that such tailored treatments could cure debilitating and/or deadly diseases with far less risk of the serious side effects often associated with more standardized treatments.

While up until this point, technology limitations have stymied progress in the field of precision medicine, new big data and artificial intelligence (AI) tools may now allow scientists to proceed faster than ever before. Data—and the ability to store, secure, process and interpret vast amounts of it in a way the human brain simply cannot—will be critical in this transformation of healthcare. And that bodes well for companies that can provide and put to use the necessary technology.

Also essential will be a strong commitment from governments, healthcare agencies and regulators, which seems to be taking shape.

We explore where precision medicine can take us, what it will take to get there and the potential investment implications.

 

Examining the precision medicine trend in healthcare


Precision medicine, over time, has the potential to bring targeted, life-saving treatments to countless individuals suffering from a wide range of previously incurable diseases, without destroying the quality of the lives it saves.

Consider one early example from 2018—a treatment called “milasen,” named for the eight-year-old who received this custom treatment for Batten’s disease. Milasen is believed to be the first drug developed for a unique, individual patient.1 Milasen is essentially a custom piece of RNA2 designed by doctors to block certain negative effects of a mutated gene within the patient’s DNA. The treatment worked, and the positive impact of the treatment was visible in the patient within months.

What about cancer? Can a similar method be used to create precision medicines that could treat 18.1 million new cancer cases and potentially prevent another 9.6 million deaths worldwide, as seen in 2018?3

Precision medicine is already being closely studied for its potential in oncology. Doctors may be able to use it to create targeted cancer treatments that attack specific cells within the body. As opposed to chemotherapy, precision oncology may be less likely to harm healthy human cells because it takes aim only at specific tumor cells. A treatment capable of bypassing the harmful side effects of chemotherapy could be a lifesaver to many of the over 1.7 million patients diagnosed with cancer every year in the United States.4

Precision medicine also holds some promise in treating COVID-19. Researchers have found that a variety of characteristics such as age, previous conditions and some less obvious markers appear to be linked to the recovery time of the disease. For example, scientists are currently exploring the link between the severity of COVID-19 symptoms and higher testosterone levels.5 Essentially, COVID-19 can use two human proteins to enter human cells, one being TMPRSS2. Researchers at Columbia University Irving Medical Center found that the number of TMPRSS2 molecules in cells can be reduced by lowering testosterone, indicating that drugs that reduce testosterone levels could help lessen the severity of COVID-19. Depending on findings, this could lead to the development of a precision medicine able to treat COVID-19 infections by lowering testosterone in individuals with specific levels of the hormone.

And that is just the beginning. The possibilities extend to conditions like genetic blindness, muscular dystrophy, diabetes, heart disease and more.

 

Applying precision medicine innovations to all healthcare solutions


For precision medicine to become a viable option for everyone, data is needed, lots of data—as well as the commitment of governments, healthcare agencies and regulators to provide a supportive framework.

To design treatments for individuals or specific groups, scientists need a vast dataset of patient histories to analyze which treatments work best for which patients.

One major effort to amass the breadth and depth of required data is the “All of Us” campaign. This research program run through the National Institutes of Health (NIH) is working to enroll over 1 million Americans into a health data-gathering program aimed at furthering the cause of precision medicine. Participants in this 10-year study will be requested to provide a myriad of information on their medical histories, lifestyles, environment and behavior. The data will be used to explore how these factors can impact the vulnerability of specific patients to various diseases and which treatments have the greatest potential for different patient types. As of the end of 2019, the “All of Us” program had enrolled approximately 275,000 participants.6

The NIH is not the only organization developing large sets of patient medical data to help develop the field of precision medicine. Other research includes the Yale Precision Medicine Initiative, which aims to sequence genomes from 100,000 patients7 and collect other patient medical history. Similarly, the United Kingdom’s National Health Service and Genomics England are combining research efforts to sequence genomes from 5 million people by 2025.8

Governments and health officials have taken notice of the huge potential for precision medicine as well the incredible hurdles in its path. Health agencies in the United States and other countries have already committed to building out massive healthcare data infrastructures to accommodate scientific research in precision medicine. On the regulatory side, the U.S. Food & Drug Administration (FDA) recognizes the new regulatory issues likely to come with these transformational developments in healthcare. However, the FDA also recognizes the tremendous promise of precision medicine, not just for the distant future, but also for the coming years. In 2019, Acting FDA Commissioner Sharpless said, “In just the past few years, we’ve seen transformative technologies like artificial intelligence, whole genomic sequencing, and cell- or gene-based therapies result in FDA-approved or cleared products that are advancing precision medicine—delivering the right intervention to the right patient, at the right time.”9

While the FDA is still working to develop answers to the regulatory questions, there is no doubt the field of precision medicine represents a new frontier in healthcare innovation.

 

Investment impact of healthcare trends and innovations


Several types of companies may help drive the development of precision medicine.

Data-driven medical research companies, particularly those with prowess in AI and machine learning, will lead the way in researching new precision medicines for patients. Just as financial firms can determine a consumer’s credit score based on almost every aspect of a person’s financial history, healthcare companies may soon be able to analyze a patient’s entire medical history to determine which treatment could be best for that unique individual. These are the companies that will be able to take vast datasets and interpret them to determine which treatment options to explore and conduct further research on for any given patient. Large pharmaceutical companies that focus on cell therapy and/or immune-oncology treatments could be key in this category.

Medical diagnostics and analysis companies could lead the way toward the development and implementation of precision health. Medical testing and analytics companies that focus on gene sequencing, specialized medical screening through DNA analysis, or molecular modification as remedies could all bring cutting-edge treatments to the healthcare industry. Companies in this category would not only need advanced medical technology, but also the capability to examine vast datasets of medical records and trials.

 

Focus your healthcare investments on enabling technologies


Innovations in big data, AI and medical science are leading us to a previously unimaginable frontier—where treatments for some of the most devastating diseases can be uniquely designed to match an individual patient’s personal profile and genetic makeup. Think of a world where tailored treatments, even for previously incurable diseases, can be delivered with potentially minimal side effects. From so many angles, that is a world worth investing in.


1. “Scientists Designed a Drug for Just One Patient. Her Name Is Mila.” The New York Times, October 9, 2019.
2. Ribonucleic acid (RNA) is a nucleic acid present in all living cells.
3. International Agency for Research on Cencer. “Latest Global Cancer Data:Cancer Burden Rises to 18.1 Million New Cases and 9.6 Million Cancer Deaths in 2018.” World Health Organization, 12 Sept. 2018, www.who.int/cancer/PRGlobocanFinal.pdf
4. “Understanding Precision Medicine.” U.S. Food & Drug Administration, 2019.
5. “Lowering Testosterone May Reduce Severity of COVID-19.” Columbia University Irving Medical Center, May 15, 2020.
6. “Life Science Tools & Diagnostics: 2020 Outlook.” J.P. Morgan North America Equity Research, Life Science Tools & Diagnostics, SMid Medical Technology Team. December 2019.
7. “For cancer treatment and more, genetic-based precision medicine holds a lot of promise.” Connecticut Magazine, May 26, 2020.
8. “Matt Hancock announces ambition to map 5 million genomes.” Department of Health and Social Care, Gov.uk. October 2, 2018.
9. “A Message from FDA’s Acting Commissioner,” 2019 FDA Science Forum. Norman E. “Ned” Sharpless, MD, Acting Commissioner, FDA. September 11, 2019.

 

 

 

 

IMPORTANT INFORMATION

This material is for information purposes only, and may inform you of certain products and services offered by J.P. Morgan’s wealth management businesses, part of JPMorgan Chase & Co. (“JPM”). Please read all Important Information.

 

GENERAL RISKS & CONSIDERATIONS

Any views, strategies or products discussed in this video may not be appropriate for all individuals and are subject to risks. Investors may get back less than they invested, and past performance is not a reliable indicator of future results. Asset allocation/diversification does not guarantee a profit or protect against loss. Nothing in this video should be relied upon in isolation for the purpose of making an investment decision. You are urged to consider carefully whether the services, products, asset classes (e.g. equities, fixed income, alternative investments, commodities, etc.) or strategies discussed are suitable to your needs. You must also consider the objectives, risks, charges, and expenses associated with an investment service, product or strategy prior to making an investment decision.  For this and more complete information, including discussion of your goals/situation, contact your J.P. Morgan team.

 

NON-RELIANCE

Certain information contained in this video is believed to be reliable; however, JPM does not represent or warrant its accuracy, reliability or completeness, or accept any liability for any loss or damage (whether direct or indirect) arising out of the use of all or any part of this video. No representation or warranty should be made with regard to any computations, graphs, tables, diagrams or commentary in this video, which are provided for illustration/reference purposes only. The views, opinions, estimates and strategies expressed in this video constitute our judgment based on current market conditions and are subject to change without notice. JPM assumes no duty to update any information in the event that such information changes. Views, opinions, estimates and strategies expressed herein may differ from those expressed by other areas of JPM, views expressed for other purposes or in other contexts, and this should not be regarded as a research report. Any projected results and risks are based solely on hypothetical examples cited, and actual results and risks will vary depending on specific circumstances. Forward-looking statements should not be considered as guarantees or predictions of future events.

Nothing in this video shall be construed as giving rise to any duty of care owed to, or advisory relationship with, you or any third party.  Nothing in this video shall be regarded as an offer, solicitation, recommendation or advice (whether financial, accounting, legal, tax or other) given by J.P. Morgan and/or its officers or employees, irrespective of whether or not such communication was given at your request. J.P. Morgan and its affiliates and employees do not provide tax, legal or accounting advice. You should consult your own tax, legal and accounting advisors before engaging in any financial transactions. 

 

IMPORTANT INFORMATION ABOUT YOUR INVESTMENTS AND POTENTIAL CONFLICTS OF INTEREST

Conflicts of interest will arise whenever JPMorgan Chase Bank, N.A. or any of its affiliates (together, “J.P. Morgan”) have an actual or perceived economic or other incentive in its management of our clients’ portfolios to act in a way that benefits J.P. Morgan. Conflicts will result, for example (to the extent the following activities are permitted in your account): (1) when J.P. Morgan invests in an investment product, such as a mutual fund, structured product, separately managed account or hedge fund issued or managed by JPMorgan Chase Bank, N.A. or an affiliate, such as J.P. Morgan Investment Management Inc.; (2) when a J.P. Morgan entity obtains services, including trade execution and trade clearing, from an affiliate; (3) when J.P. Morgan receives payment as a result of purchasing an investment product for a client’s account; or (4) when J.P. Morgan receives payment for providing services (including shareholder servicing, recordkeeping or custody) with respect to investment products purchased for a client’s portfolio. Other conflicts will result because of relationships that J.P. Morgan has with other clients or when J.P. Morgan acts for its own account.

Investment strategies are selected from both J.P. Morgan and third-party asset managers and are subject to a review process by our manager research teams. From this pool of strategies, our portfolio construction teams select those strategies we believe fit our asset allocation goals and forward looking views in order to meet the portfolio's investment objective.

As a general matter, we prefer J.P. Morgan managed strategies. We expect the proportion of J.P. Morgan managed strategies will be high (in fact, up to 100 percent) in strategies such as, for example, cash and high-quality fixed income, subject to applicable law and any account-specific considerations.

While our internally managed strategies generally align well with our forward-looking views, and we are familiar with the investment processes as well as the risk and compliance philosophy of the firm, it is important to note that J.P. Morgan receives more overall fees when internally managed strategies are included. We offer the option of choosing to exclude J.P. Morgan managed strategies (other than cash and liquidity products) in certain portfolios.

 

LEGAL ENTITY, BRAND & REGULATORY INFORMATION

In the United States, bank deposit accounts and related services, such as checking, savings and bank lending, are offered by JPMorgan Chase Bank, N.A. Member FDIC.

JPMorgan Chase Bank, N.A. and its affiliates (collectively "JPMCB") offer investment products, which may include bank managed investment accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC (“JPMS”), a member of FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPMS and CIA are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

In Luxembourg, material is issued by J.P. Morgan Bank Luxembourg S.A. (JPMBL), with registered office at European Bank and Business Centre, 6 route de Treves, L-2633, Senningerberg, Luxembourg. R.C.S Luxembourg B10.958. Authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A. is authorized as a credit institution in accordance with the Law of 5th April 1993. In the United Kingdom,  material is issued by J.P. Morgan Bank Luxembourg S.A– London Branch. Prior to Brexit,(Brexit meaning that the UK leaves the European Union under Article 50 of the Treaty on European Union, or, if later, loses its ability to passport financial services between the UK and the remainder of the EEA), J.P. Morgan Bank Luxembourg S.A– London Branch is subject to limited regulation by the Financial Conduct Authority and the Prudential Regulation Authority. Details about the extent of our regulation by the Financial Conduct Authority and the Prudential Regulation Authority are available from us on request. In the event of Brexit, in the UK, J.P. Morgan Bank Luxembourg S.A.– London Branch is authorised by the Prudential Regulation Authority, subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. In Spain, material is distributed by J.P. Morgan Bank Luxembourg S.A., Sucursal en España, with registered office at Paseo de la Castellana, 31, 28046 Madrid, Spain. J.P. Morgan Bank Luxembourg S.A., Sucursal en España is registered under number 1516 within the administrative registry of  the Bank of Spain and supervised by the Spanish Securities Market Commission (CNMV). In Germany, material is distributed by J.P. Morgan Bank Luxembourg S.A., Frankfurt Branch, registered office at Taunustor 1 (TaunusTurm), 60310 Frankfurt, Germany, jointly supervised by the Commission de Surveillance du Secteur Financier (CSSF) and the European Central Bank (ECB), and in certain areas also supervised by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). In Italy, material is distributed by J.P. Morgan Bank Luxembourg S.A– Milan Branch, registered office at Via Catena Adalberto 4, Milan 20121, Italy and regulated by Bank of Italy and the Commissione Nazionale per le Società e la Borsa (CONSOB). In the Netherlands, material is distributed by J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch, with registered office at World Trade Centre, Tower B, Strawinskylaan 1135, 1077 XX, Amsterdam, The Netherlands. J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF in Luxembourg; J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is also authorised and supervised by De Nederlandsche Bank (DNB) and the Autoriteit Financiële Markten (AFM) in the Netherlands. Registered with the Kamer van Koophandel as a branch of J.P. Morgan Bank Luxembourg S.A. under registration number 71651845. In Denmark, material is distributed by J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. with registered office at Kalvebod Brygge 39-41, 1560 København V, Denmark. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A.is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. is also subject to the supervision of Finanstilsynet (Danish FSA) and registered with Finanstilsynet as a branch of J.P. Morgan Bank Luxembourg S.A. under code 29009.  In Sweden, material is distributed by J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial, with registered office at Hamngatan 15, Stockholm, 11147, Sweden. J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A., Stockholm Branch is also subject to the supervision of Finansinspektionen (Swedish FSA). Registered with Finansinspektionen as a branch of J.P. Morgan Bank Luxembourg S.A..  In France, material is distributed by JPMorgan Chase Bank, N.A. (“JPMCB”), Paris branch, which is regulated by the French banking authorities Autorité de Contrôle Prudentiel et de Résolution and Autorité des Marchés Financiers. In Switzerland, material is distributed by J.P. Morgan (Suisse) SA, which is regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA).

In Hong Kong, material is distributed by JPMCB, Hong Kong branch. JPMCB, Hong Kong branch is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission of Hong Kong. In Hong Kong, we will cease to use your personal data for our marketing purposes without charge if you so request. In Singapore, material is distributed by JPMCB, Singapore branch. JPMCB, Singapore branch is regulated by the Monetary Authority of Singapore. Dealing and advisory services and discretionary investment management services are provided to you by JPMCB, Hong Kong/Singapore branch (as notified to you). Banking and custody services are provided to you by JPMCB Singapore Branch. The contents of this video have not been reviewed by any regulatory authority in Hong Kong, Singapore or any other jurisdictions. You are advised to exercise caution in relation to this video. If you are in any doubt about any of the contents of this video, you should obtain independent professional advice. For materials which constitute product advertisement under the Securities and Futures Act and the Financial Advisers Act, this advertisement has not been reviewed by the Monetary Authority of Singapore. JPMorgan Chase Bank, N.A., a national banking association chartered under the laws of the United States, and as a body corporate, its shareholder’s liability is limited.

With respect to countries in Latin America, the distribution of material may be restricted in certain jurisdictions. We may offer and/or sell to you securities or other financial instruments which may not be registered under, and are not the subject of a public offering under, the securities or other financial regulatory laws of your home country. Such securities or instruments are offered and/or sold to you on a private basis only. Any communication by us to you regarding such securities or instruments, including without limitation the delivery of a prospectus, term sheet or other offering document, is not intended by us as an offer to sell or a solicitation of an offer to buy any securities or instruments in any jurisdiction in which such an offer or a solicitation is unlawful. Furthermore, such securities or instruments may be subject to certain regulatory and/or contractual restrictions on subsequent transfer by you, and you are solely responsible for ascertaining and complying with such restrictions. To the extent this content makes reference to a fund, the Fund may not be publicly offered in any Latin American country, without previous registration of such fund´s securities in compliance with the laws of the corresponding jurisdiction. Public offering of any security, including the shares of the Fund, without previous registration at Brazilian Securities and Exchange Commission–CVM is completely prohibited. Some products or services contained herein might not be currently provided by the Brazilian and Mexican platforms.

JPMorgan Chase Bank, N.A. (JPMCBNA) (ABN 43 074 112 011/AFS Licence No: 238367) is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation Authority. Material provided by JPMCBNA in Australia is to “wholesale clients” only. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Corporations Act 2001 (Cth). Please inform us if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

JPMS is a registered foreign company (overseas) (ARBN 109293610) incorporated in Delaware, U.S.A. Under Australian financial services licensing requirements, carrying on a financial services business in Australia requires a financial service provider, such as J.P. Morgan Securities LLC (JPMS), to hold an Australian Financial Services Licence (AFSL), unless an exemption applies. JPMS is exempt from the requirement to hold an AFSL under the Corporations Act 2001 (Cth) (Act) in respect of financial services it provides to you, and is regulated by the SEC, FINRA and CFTC under US laws, which differ from Australian laws. Material provided by JPMS in Australia is to “wholesale clients” only. The information provided herein is not intended to be, and must not be, distributed or passed on, directly or indirectly, to any other class of persons in Australia. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Act. Please inform us immediately if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

This content has not been prepared specifically for Australian investors. It:

  • may contain references to dollar amounts which are not Australian dollars;
  • may contain financial information which is not prepared in accordance with Australian law or practices;
  • may not address risks associated with investment in foreign currency denominated investments; and
  • does not address Australian tax issues.

References to “J.P. Morgan” are to JPM, its subsidiaries and affiliates worldwide. “J.P. Morgan Private Bank” is the brand name for the private banking business conducted by JPM. This is intended for your personal use and should not be circulated to or used by any other person, or duplicated for non-personal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan team. 

© 2020 JPMorgan Chase & Co. All rights reserved.

Check the background of Our Firm and Investment Professionals on FINRA's BrokerCheck

To learn more about J. P. Morgan’s investment business, including our accounts, products and services, as well as our relationship with you, please review our  J.P. Morgan Securities LLC Form CRS and  Guide to Investment Services and Brokerage Products.

This website is for informational purposes only, and not an offer, recommendation or solicitation of any product, strategy service or transaction. Any views, strategies or products discussed on this site may not be appropriate or suitable for all individuals and are subject to risks. Prior to making any investment or financial decisions, an investor should seek individualized advice from a personal financial, legal, tax and other professional advisors that take into account all of the particular facts and circumstances of an investor's own situation. 

This website provides information about the brokerage and investment advisory services provided by J.P. Morgan Securities LLC (“JPMS”). When JPMS acts as a broker-dealer, a client's relationship with us and our duties to the client will be different in some important ways than a client's relationship with us and our duties to the client when we are acting as an investment advisor. A client should carefully read the agreements and disclosures received (including our Form ADV disclosure brochure, if and when applicable) in connection with our provision of services for important information about the capacity in which we will be acting.

INVESTMENT AND INSURANCE PRODUCTS ARE: • NOT FDIC INSURED • NOT INSURED BY ANY FEDERAL GOVERNMENT AGENCY • NOT A DEPOSIT OR OTHER OBLIGATION OF, OR GUARANTEED BY, JPMORGAN CHASE BANK, N.A. OR ANY OF ITS AFFILIATES • SUBJECT TO INVESTMENT RISKS, INCLUDING POSSIBLE LOSS OF THE PRINCIPAL AMOUNT INVESTED
Equal Housing Opportunity logo

J.P. Morgan Chase Bank N.A., Member FDIC Not a commitment to lend. All extensions of credit are subject to credit approval 

“J.P. Morgan Securities” is a brand name for a wealth management business conducted by JPMorgan Chase & Co. (“JPMC”) and its subsidiaries worldwide. JPMorgan Chase Bank, N.A. and its affiliates (collectively “JPMCB”) offer investment products, which may include bank managed accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC (“JPMS”), a member of FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPMS and CIA are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

Please read additional Important Information in conjunction with these pages.